Table 2. Patient characteristics Patient... | American Society of Hematology

Table 2.

Patient characteristics

Patient no.				ANC/mm³			Platelet count/mm³			Reticulocyte count/mm³			Follow-up, mo
Patient no.		Age, y	Ethnicity	Sex	Before	After	Before	After	Before	After	TI^*	Response	Follow-up, mo
1	57	White	F	1852	3148	45	78	55	134	T1	CR at 5 mo	31
2	43	White	M	670	1360	45	98	49	45		CR at 4 mo	32
3	58	White	F	667	1490	78	80	57	55		PR	25
4	14	Asian	F	2832	ND	5	ND	4	ND		LTF	LTF
5	53	White	F	888	786	55	61	96	66		NR	25
6	43	Hispanic	F	1200	1398	65	32	119	153		NR	24
7	41	White	M	625	494	34	39	72	79		NR	23
8	30	White	M	616	584	24	33	53	51		NR	22
9	9	White	F	1088	2400	35	30	22	134	T1	PR	21
10	37	White	F	3012	3229	33	26	21	28		NR	19
11	40	Hispanic	F	760	1124	18	20	58	59		NR	17
12	30	Hispanic	M	1068	1225	115	111	22	22		NR	20
13	25	White	M	1293	1060	33	36	71	102		NR	4
14	26	White	M	804	928	23	22	34	36		NR	10
15	67	Asian	M	800	100	47	57	70	115		PR	13
16	38	White	F	1134	1800	51	51	35	105		PR	11
17	24	Asian	F	1378	500	25	24	72	65		NR	20

Patient no.				ANC/mm³			Platelet count/mm³			Reticulocyte count/mm³			Follow-up, mo
Patient no.		Age, y	Ethnicity	Sex	Before	After	Before	After	Before	After	TI^*	Response	Follow-up, mo
1	57	White	F	1852	3148	45	78	55	134	T1	CR at 5 mo	31
2	43	White	M	670	1360	45	98	49	45		CR at 4 mo	32
3	58	White	F	667	1490	78	80	57	55		PR	25
4	14	Asian	F	2832	ND	5	ND	4	ND		LTF	LTF
5	53	White	F	888	786	55	61	96	66		NR	25
6	43	Hispanic	F	1200	1398	65	32	119	153		NR	24
7	41	White	M	625	494	34	39	72	79		NR	23
8	30	White	M	616	584	24	33	53	51		NR	22
9	9	White	F	1088	2400	35	30	22	134	T1	PR	21
10	37	White	F	3012	3229	33	26	21	28		NR	19
11	40	Hispanic	F	760	1124	18	20	58	59		NR	17
12	30	Hispanic	M	1068	1225	115	111	22	22		NR	20
13	25	White	M	1293	1060	33	36	71	102		NR	4
14	26	White	M	804	928	23	22	34	36		NR	10
15	67	Asian	M	800	100	47	57	70	115		PR	13
16	38	White	F	1134	1800	51	51	35	105		PR	11
17	24	Asian	F	1378	500	25	24	72	65		NR	20

Seventeen patients with mAA were treated with daclizumab. Of these, 16 were evaluable; patient no. 5 was lost to follow-up before the 3-month evaluation period. The ANC, absolute reticulocyte count, and platelet counts on entry to the study are shown.

Blood counts are the average of 3 consecutive measurements performed prior to study entry and 3 months after the last dose of daclizumab (first course as in the case of patient 1).

TI indicates transfusion independence; CR, complete response; PR, partial response; ND, not done; LTF, lost to follow-up; NR, no response.

Transfusion independence in patients who were previously transfusion dependent.

View Large

This Feature Is Available To Subscribers Only